Freedom Broker initiated coverage of Inogen with a Buy rating and $12 price target. The firm says Inogen is a respiratory-focused company and home medical equipment provider transitioning from a pure-play portable oxygen concentrator manufacturer into a broader respiratory care platform. The company is entering a phase of improving operating efficiency, the analyst tells investors in a research note.
